Efforts to maintain the quality of Life for patients with malignant lymphoma undergoing chemotherapy
Not Applicable
- Conditions
- Malignant lymphoma
- Registration Number
- JPRN-UMIN000026758
- Lead Sponsor
- Toho University Medical Center Sakura Hospital,Center for Diabetes, Metabolism and Endocrinology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1)multiple organ failure 2)progressive diseases during R-CHOP therapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are targeted to improve QOL in malignant lymphoma patients during chemotherapy in JPRN-UMIN000026758?
How does this trial's intervention compare to standard supportive care in maintaining QOL for lymphoma patients undergoing chemotherapy?
Which biomarkers predict response to QOL-enhancing strategies in malignant lymphoma subtypes like DLBCL or follicular lymphoma?
What adverse events are associated with interventions aimed at maintaining QOL during chemotherapy for malignant lymphoma, and how are they managed?
Are there combination therapies or novel compounds being evaluated alongside chemotherapy to enhance QOL in malignant lymphoma patients?